Enrichment of circulating tumor DNA

Patent metadata

Field	Value
Publication number	US-12351879-B2
Application number	US-202418665479-A
Country	US
Kind code	B2
Filing date	May 15, 2024
Priority date	Mar 22, 2016
Publication date	Jul 8, 2025
Grant date	Jul 8, 2025

Abstract

The present disclosure relates to methods for detecting unique genetic signatures derived from markers such as, for example, mutations, somatic or germ-line, in nucleic acids obtained from biological samples. The sensitivity of the methods provides for detection of mutations associated with a disease, e.g., cancer mutations, or with inherited disease, e.g., an autosomal recessive disease, in a noninvasive manner at ultra-low proportions of sequences carrying mutations to sequences carrying normal, e.g., non-cancer sequences, or a reference sequence, e.g., a human reference genome.

First claim

The invention claimed is:

1. An enriched DNA fraction, comprising cell free DNA (cfDNA) fragments from a patient with a prior diagnosis of cancer, the cfDNA fragments comprising a plurality of at least 10 patient-specific and tumor-specific somatic mutations, wherein the at least 10 patient-specific and tumor-specific somatic mutations comprise a mixture of (i) somatic mutations associated with the patient's cancer and (ii) somatic mutations in non-coding sequences that are not known to be associated with the patient's cancer, wherein each cfDNA fragment comprises a ligated heterologous tag, adapter sequence, or molecular barcode, and wherein the enriched DNA fraction was obtained by:
(a) extracting cell-free DNA fragments (cfDNA) from a fluid sample of whole blood, plasma, or serum obtained from the patient;
(b) enriching a fraction of DNA corresponding to the plurality of at least 10 patient-specific and tumor-specific somatic mutation sequences from the extracted cfDNA fragments by:
(i) hybrid capture-based enrichment;
(ii) PCR-target enrichment; or
(iii) on-sequencer enrichment;

wherein the plurality of at least 10 patient-specific and tumor-specific somatic mutation sequences are obtained by sequencing genomic DNA from a tumor sample from the patient and sequencing genomic DNA from a non-tumor sample from the patient, and wherein the at least 10 patient-specific and tumor-specific somatic mutation sequences are present in sequences of genomic DNA from the tumor sample but are not present in sequences of genomic DNA from a non-tumor sample from the patient.

2. The enriched DNA fraction of claim 1 , wherein hybrid capture-based enrichment is used to enrich the DNA fraction of fragments comprising the plurality of at least 10 patient-specific and tumor-specific somatic mutations.

3. The enriched DNA fraction of claim 2 , wherein hybrid capture-based enrichment comprises:
(i) contacting the extracted cfDNA from (a) with a plurality of oligonucleotides that each comprise a nucleic acid sequence that is capable of hybridizing to one of the patient-specific and tumor-specific somatic mutations, and
(ii) selectively enriching cfDNA fragments that hybridize to the plurality of oligonucleotides.

4. The enriched DNA fraction of claim 1 , wherein the enriched DNA fraction comprises cfDNA fragments that collectively comprise at least 10 different patient-specific and tumor-specific somatic mutations.

5. The enriched DNA fraction of claim 1 , wherein the DNA fraction is enriched for cfDNA fragments averaging less than about 200 base pairs in length.

6. The enriched DNA fraction of claim 1 , wherein the fluid sample is obtained from the patient during a cancer treatment, following completion of a cancer treatment, while the patient is in remission, or coinciding with or prior to surgery.

7. An enriched DNA fraction, comprising circulating tumor DNA (ctDNA) fragments comprising at least 10 patient-specific and tumor-specific somatic mutations, wherein each cfDNA fragment comprises a ligated heterologous tag, adapter sequence, or molecular barcode, and wherein the enriched DNA fraction was obtained by:
(a) obtaining a tumor sample and a non-tumor sample from a patient with a prior diagnosis of cancer;
(b) sequencing DNA from the tumor sample and sequencing DNA from the non-tumor sample, thereby obtaining sequences of DNA from the tumor sample and sequences of genomic DNA from the non-tumor sample; and
at one or more timepoints subsequent to (a) and (b) and after the patient has received a treatment for cancer or while the patient is in remission,
(c) obtaining a fluid sample of whole blood, plasma, or serum from the patient;
(d) extracting cell-free DNA (cfDNA) from the sample;
(e) enriching, from the extracted cfDNA, a DNA fraction of ctDNA fragments comprising a set of at least 10 patient-specific and tumor-specific somatic mutations that are present in the sequences of DNA from the tumor sample but not present in the sequences of DNA from the non-tumor sample, wherein enriching comprises:
(i) hybrid capture-based enrichment,
(ii) PCR-target enrichment, or
(iii) on-sequencer enrichment;

wherein the at least 10 patient-specific and tumor-specific somatic mutations comprise a mixture of (i) somatic mutations associated with the patient's cancer and (ii) somatic mutations in non-coding sequences that are not known to be associated with the patient's cancer.

8. The enriched DNA fraction of claim 7 , wherein hybrid capture-based enrichment is used to enrich the ctDNA fraction of fragments comprising the at least 10 patient-specific and tumor-specific somatic mutations.

9. The enriched DNA fraction of claim 8 , wherein hybrid capture-based enrichment comprises:
(i) contacting the extracted cfDNA from (b) with a plurality of oligonucleotides that each comprise a nucleic acid sequence that is capable of hybridizing to one of the patient-specific and tumor-specific somatic mutations, and
(ii) selectively enriching ctDNA fragments that hybridize to the plurality of oligonucleotides.

10. The enriched DNA fraction of claim 9 , wherein the plurality of oligonucleotides is capable of detecting at least 50 different patient-specific and tumor-specific somatic mutations.

11. The enriched DNA fraction of claim 7 , wherein the enriched DNA fraction comprises cfDNA fragments that collectively comprise at least 10 different patient-specific and tumor-specific somatic mutations.

12. The enriched DNA fraction of claim 7 , wherein the DNA fraction is enriched for cfDNA fragments averaging less than about 200 base pairs in length.

13. The enriched DNA fraction of claim 7 , wherein the fluid sample is obtained from the patient during a cancer treatment, following completion of a cancer treatment, while the patient is in remission, or coinciding with or prior to surgery.

14. The enriched DNA fraction of claim 7 , wherein PCR-target enrichment is used to enrich the DNA fraction of fragments comprising the set of at least 10 patient-specific and tumor-specific somatic mutations.

15. An enriched DNA fraction, comprising circulating tumor DNA (ctDNA) fragments comprising at least 10 patient-specific and tumor-specific somatic mutations, wherein the at least 10 patient-specific and tumor-specific somatic mutations comprise a mixture of (i) somatic mutations associated with the patient's cancer and (ii) somatic mutations in non-coding sequences that are not known to be associated with the patient's cancer, wherein each cfDNA fragment comprises a ligated heterologous tag, adapter sequence, or molecular barcode, and wherein the enriched DNA fraction was obtained by:
(a) obtaining a tumor sample and a non-tumor sample from the cancer patient;
(b) sequencing genomic DNA from the tumor sample and sequencing genomic DNA from the non-tumor sample, thereby obtaining sequences of genomic DNA from the tumor sample and sequences of genomic DNA from the non-tumor sample;
(c) aligning the sequences of genomic DNA from the tumor sample to a reference human genome that is not from the patient thereby obtaining a set of tumor-specific mutations and further obtaining from the set of tumor-specific mutations a set of at least 10 patient-specific and tumor-specific somatic mutation sequences that are present in the sequences of genomic DNA from the tumor sample but not present in the sequences of genomic DNA from the non-tumor sample;
(d) extracting cell-free DNA fragments (cfDNA) from a substantially cell-free fluid sample of blood plasma or blood serum obtained from the cancer patient;
(e) contacting the extracted cfDNA fragments with a plurality of ol

Assignees

• Myriad Womens Health Inc

Inventors

• Maguire Jared Robert
• Chu Clement S
• Haque Imran Saeedul
• Evans Eric Andrew
• Welker Noah

Classifications

• G01N35/0099

  comprising robots or similar manipulators (robots per se B25J) · CPC title

• C12Q1/6818 Primary

  involving interaction of two or more labels, e.g. resonant energy transfer · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6874

  involving nucleic acid arrays, e.g. sequencing by hybridisation · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title